Variable | Univariate analysis | Number of observations missing | Multivariable analysis | ||
Parameter estimate (95% CI) | p Value | Parameter estimate (95% CI) | p-Value | ||
Age | 0.064 (0.023 to 0.106) | 0.0024 | 0 | 0.057 (0.015 to 0.099) | 0.0078 |
Gender (male) | 0.722 (−0.134 to 1.578) | 0.0982 | 0 | NS | NS |
Education (<13 years) | 0.623 (−0.461 to 1.706) | 0.2590 | 0 | – | – |
Ethnicity (hispanic) | −2.354 (−5.011 to 0.302) | 0.0822 | 0 | NS | NS |
Race (white) | 0.457 (−1.048 to 1.961) | 0.5510 | 0 | – | – |
Family history of PD | −0.664 (−1.601 to 0.274) | 0.1649 | 1 | NS | NS |
Age-adjusted/sex-adjusted UPSIT (anosmia) | 0.332 (−0.523 to 1.186) | 0.4458 | 0 | – | – |
MDS-UPDRS Part II score | 0.061 (−0.039 to 0.161) | 0.2312 | 0 | – | – |
MDS-UDPRS Part III score | 0.000 (−0.046 to 0.047) | 0.9884 | 0 | -– | – |
Modified Schwab and England Activities of Daily Living Scale | −0.006 (−0.077 to 0.065) | 0.8631 | 0 | – | – |
Hoehn and Yahr (Stage 1) | −0.053 (−0.873 to 0.767) | 0.8991 | 0 | – | – |
TD/non-TD classification | 0.236 (−0.665 to 1.137) | 0.6067 | 0 | – | – |
PIGD score | −0.987 (−2.797 to 0.824) | 0.2845 | 0 | – | – |
Tremor score | −0.111 (−1.383 to 1.162) | 0.8641 | 0 | – | – |
Side most affected (left) | 0.565 (−0.194 to 1.323) | 0.1440 | 0 | NS | NS |
Disease duration | 0.033 (−0.029 to 0.095) | 0.2905 | 0 | – | – |
Age of PD onset | 0.060 (0.019 to 0.101) | 0.0041 | 7 | NS | NS |
Contralateral caudate | −0.329 (−1.088 to 0.431) | 0.3952 | 4 | – | – |
Ipsilateral caudate | −0.530 (−1.224 to 0.164) | 0.1341 | 4 | NS | NS |
Contralateral putamen | −0.887 (−2.565 to 0.791) | 0.2993 | 4 | – | – |
Ipsilateral putamen | −1.298 (−2.381 to 0.215) | 0.0189 | 4 | NS | NS |
A-Beta | −0.005 (−0.009 to 0.002) | 0.0024 | 9 | −0.005 (−0.008 to 0.002) | 0.0046 |
t-tau | −0.003 (−0.006 to 0.001) | 0.0966 | 13 | NS | NS |
p-tau | −0.001 (−0.004 to 0.003) | 0.6422 | 11 | – | – |
t-tau/A-Beta | −0.001 (−0.004 to 0.003) | 0.6951 | 13 | – | – |
p-tau/A-Beta | 0.002 (−0.001 to 0.006) | 0.2024 | 11 | – | – |
p-tau/t-tau | 0.001 (−0.002 to 0.005) | 0.5213 | 15 | – | – |
α-Synuclein | −0.002 (−0.005 to 0.002) | 0.3010 | 9 | – | – |
Report generated on data submitted as of 4 January 2016.
*NMS is defined as MDS-UPDRS Part 1 score.
MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; NMS, non-motor symptoms; PD, Parkinson’s disease;N.S, not significant; PIGD, postural instability gait disorder; TD, tremor dominant; UPSIT, University of Pennsylvania Smell Identification Test.